In the world of pharmaceutical development, the compression of powder into tablets may seem simple, but behind every successful compact lies a balance of physics, materials science, and manufacturing expertise. Mastering that balance is down to the compaction simulator a device whose evolution mirrors the pharmaceutical industry’s growing demand for precision, efficiency, and data-driven formulation. 

Among the leaders in this niche field is Merlin Powder Characterisation Ltd, a UK-based laboratory that has turned advanced compaction simulation into an indispensable tool for pharmaceutical innovators worldwide. 

A Brief History of Compaction Simulators- 

The concept of compaction simulation originated in the late 1970s as pharmaceutical researchers realised that the ability to be able to manufacture products simply and cheaply were just as important as the efficacy of the drug itself. Traditional single-station tablet presses, while useful, couldn’t replicate the speeds seen in high-speed rotary tablet presses used in production. Products which worked well in the laboratory were found incapable of being manufactured at production, scale affecting commercialisation.   In response, early research institutions developed instrumented presses to collect data on force-displacement profiles.  

In the early 1990s the pharmaceutical sector saw the advancement of instrumentation and introduction of computer processing of raw data which speeded up experimentation and the appeal of hydraulic compaction simulators.  Formulation scientists in larger companies had access to these devices capable of replicating industrial press profiles with high precision and very low sample volumes. These instruments became crucial in formulation screening, troubleshooting, and scale-up risk reduction. 

In 2010s as Quality by Design and predictive modelling evolved, generating quantitative data on tablet compression was no longer a niche science but has gone mainstream, becoming an essential part of tablet development.  Compaction science information was forming an integral part of regulatory submissions. 

Introducing Merlin Powder Characterisation Ltd (established 2011) 

Merlin, based in Brierley Hill in the West Midlands, UK was built around the expertise of founders Darren and Vicki Wilkes and Elaine Harrop Stone.  The company quickly became known for its ability to reproduce production-level compression conditions in a laboratory setting.  Expanding access from the preserve of ‘Big Pharma’ to a wider audience.  Merlin is focused on offering specialist testing services, providing data-rich insights into how powders behave under compression. 

The Technology: How Simulators Work 

Modern compaction simulators, like the one used at Merlin, use servo-hydraulic or electro-mechanical actuators to control both upper and lower punch movement, mimicking the speed, pressure, and dwell time of commercial tablet presses like Fette, Korsch, or Manesty. 

Merlin’s simulator is capable of: 

• Reproducing any tablet press compression profile 

• Measuring key material properties like tensile strength, elastic recovery, and ejection force 

• Using small sample sizes 

These capabilities allow Merlin to perform: 

• Compressibility and Compactability studies 

• Manufacturability assessments 

• Lubrication efficiency evaluations 

• Bilayer tablet analysis 

• Sticking and capping risk assessments 

• Excipient screening and comparison 

Why It Matters: De-Risking Scale-Up and Supporting Sustainability 

Compaction simulation offers two big advantages: 

Cost and material savings: Companies no longer need kilogram-scale batches to screen or troubleshoot. Compaction simulators can work with just a few grams.  With API costs higher than ever, the savings in raw material costs can be significant. 

Reduced failure rates: By replicating actual production conditions early in development, clients can identify formulation risks—like sticking or poor tablet strength—before reaching costly pilot or commercial stages. If we can get it right first time, patients benefit. 

Shaping the Future of Tablet Development 

Over the past 15 years, Merlin has tested hundreds of APIs and formulations for clients ranging from global pharmaceutical giants to virtual biotech firms. It has also supported excipient manufacturers, CDMOs, and generic drug developers with critical formulation insights. 

The company’s recent leadership restructuring in June 2024and plans for growth signals a renewed focus on evidence based decision making, quality, and innovation. 

With increasing involvement in international compaction forums and ongoing work aligned with USP <1062> Tablet Compression guidelines, Merlin is not just reacting to changes in the industry, it is helping shape them.